Topic starter
12/07/2026 12:26 pm
TL;DR: The FDA’s June 2025 white paper on securing operational technology used for medical product manufacturing shifts pharmaceutical security toward connected production systems, asset visibility, zone-based segmentation, and security by design as OT ransomware rises 46 percent, according to Elisity. The real governance change is that manufacturing trust boundaries now matter as much as endpoint hardening.
Editorial analysis by NHI Mgmt Group, based on content published by Elisity: “FDA's New OT Cybersecurity Guidance: A Critical Roadmap for Pharmaceutical and Biotech Manufacturing Security”.
Key questions
Q: What is the first step when securing pharmaceutical OT environments under FDA guidance?
A: Start with a trustworthy OT asset inventory and zone model.
Q: Why do flat OT networks increase risk in pharmaceutical manufacturing?
A: Flat networks create broad implicit trust, which makes lateral movement easier if a device, workstation, or remote path is compromised.
Q: What are the signs that OT segmentation is failing in practice?
A: Look for maintenance paths that can reach more than one zone, credentials that remain usable after the job ends, and limited visibility into what the session actually touched.
Practitioner guidance
- Define manufacturing zones by process and risk Group OT assets by shared security requirements, production function, and patient-impact criticality before enforcing any conduit rules.
- Build a complete OT asset inventory Include embedded modules, software components, and communication paths so policy design is based on what is truly present, not what operators assume is present.
- Adopt identity-based least privilege for plant communications Attach rules to device identity and role so production systems can communicate only with approved peers, even when equipment moves across lines or facilities.
Bottom line: The FDA’s OT guidance pushes pharmaceutical manufacturing security toward explicit trust boundaries, not broad internal trust.
Explore further
View Full Forum → | NHI Foundation Course → | Our Services → | Read the full analysis →
12/07/2026 12:38 pm
Zone and conduit architecture is now a governance requirement, not a design preference. The FDA’s guidance makes it clear that pharmaceutical manufacturing security must be organised around controlled communication boundaries rather than ambient trust. That is a structural shift for security governance because it turns segmentation into a compliance-relevant control plane. For practitioners, the lesson is that flat or weakly segmented OT networks no longer satisfy the risk profile of connected manufacturing.
A question worth separating out:
Q: How should security teams balance FDA compliance with plant uptime?
A: Treat compliance as a design problem rather than a retrofitting exercise. The best outcome is a zone-based model that preserves deterministic production traffic while removing unnecessary trust between systems. That allows security to strengthen containment without forcing broad operational disruption.
👉 Read our full editorial: FDA OT cybersecurity guidance reshapes pharmaceutical manufacturing security